eScholarship
metadata only
CC BY
Preclinical Evaluation of Soluble Epoxide Hydrolase Inhibitor AMHDU against Neuropathic Pain
Inhibition of soluble epoxide hydrolase (sEH) is a promising therapeutic strategy for treating neuropathic pain. These inhibitors effectively reduce diabetic neuropathic pain and inflammation induced by Freund's adjuvant which makes them a suitable alternative to traditional opioids. This study show
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Efficacy of Spinal Oxytocin in Healthy Volunteers#1163460
- Pharmacological treatment for painful and symptomatic diabetic neuropathy - a systematic review and network meta-analysis / Velina Vasileva Shishkova-Stoev ; Gutachter: Sabrina Schlesinger, Brenda Wilhelma Corinna Bongaerts#983186
- Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion#683973
- Pharmacogenomics Applied to Chronic Pain Treatment in Primary Care#980448
- Preparation and evaluation of soluble epoxide hydrolase inhibitors with improved physical properties and potencies for treating diabetic neuropathic pain#1263442
Record · ID 1298561
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive